

1 **Atypical location and appearance of**
2 **chondromyxoid of the right iliac wing fibroma**
3 **in a child**

9
10
11 **ABSTRACT**

12
13
14 **Aims:** The chondromyxoid tumor is a benign primary bone tumor of cartilaginous differentiation whose
15 location is atypical and rarely described in the literature.

16
17
18 **Case report :** A 10 year old child, who consulted the emergency room of the children's
19 hospital of Rabat for a hard and painful swelling of the right iliac fossa, rapidly
20 increasing in volume. Biological tests were normal. The radiography showed a mixed
21 lytic and condensing lesion, heterogeneous, of the right iliac wing, prompting **an**
22 **magnetic resonance imaging (MRI)**

23
24
25
26
27 **Discussion :** Chondromyxoid fibroma usually affects young subjects and manifests
28 clinically as pain and swelling. Pathological fractures are common.
29 On standard radiography, in long bones, there is an eccentric geographic gap, blowing
30 out the cortex. On flat bones such as the iliac bone, the tumor is often polycyclic and
31 mixed, combining condensation and bone lysis. Intratumoral microcalcifications may be
32 encountered.
33 MRI is the key examination to evoke the diagnosis of chondromyxoid fibroma

34
35
36 **Conclusion:** Imaging and in particular MRI plays multiple and fundamental roles in
37 the management of chondromyxoid fibroma. MRI provides diagnostic guidance,
particularly in the case of atypical localization.

38 *Keywords:* chondromyxoid fibroma, child,

39
40
41
42
43 **1. INTRODUCTION**

44
45 Chondromyxoid tumor is a rare benign bone tumor, presenting 0.5% of primary bone tumors. It
46 usually involves the metaphyses of long bones.

47 The objective of our article is to illustrate an aggressive form of this tumor, of atypical location in a
48 child, by underlining the preponderant role of magnetic resonance imaging (MRI)
49 in its management
50

51 2. PRESENTATION OF THE CASE

52 A 10 year old child, who consulted the emergency room of the children's hospital of Rabat for a hard
53 and painful swelling of the right iliac fossa, rapidly increasing in volume. Biological tests were normal.
54 The radiography showed a mixed lytic and condensing lesion, heterogeneous, of the right iliac wing,
55 prompting an MRI.
56

57 The MRI showed a lesion process centered on the right iliac wing (figure 1), multi-loculated,
58 hyposignal T1, hypersignal T2 heterogeneous, containing multiple thick septa in hyposignal T2
59 enhanced by Gadolinium, without diffusion restriction. There is a compact reaction opposite, without
60 invasion of adjacent structures. There was no fatty infiltration or associated adenopathies.

61 The process was in favor of a benign origin rather than a chondrosarcoma. Chondromyxoid fibroma
62 was among the diagnoses evoked, and was histologically confirmed after biopsy of the tumor.

63 Surgical excision was indicated.

64 Tumor recurrence was objectified by a follow-up MRI performed after 5 months. It is noted that the
65 recurrence was larger than the primary tumor (Figure 1 d).
66

67 3. DISCUSSION

68 Chondromyxoid fibroma usually affects young subjects and manifests clinically as pain and swelling.
69 Pathological fractures are common [1,5].

70 On standard radiography, in long bones, there is an eccentric geographic gap, blowing out the cortex.
71 On flat bones such as the iliac bone, the tumor is often polycyclic and mixed, combining condensation
72 and bone lysis. Intratumoral microcalcifications may be encountered [2,10].

73 magnetic resonance imaging (MRI) is the key examination to evoke the diagnosis of chondromyxoid
74 fibroma. The myxoid component appears hyposignal on the T1-weighted sequence, hypersignal on
75 the T2-weighted sequence, and enhanced by Gadolinium. MRI can also detect other associated
76 intratumoral components: fibrous, cystic and calcific [3,4,6,7].

77 Chondromyxoid fibroma is characterized by the absence of intramedullary extension, which makes it
78 possible to differentiate its aggressive form from a chondrosarcoma, the latter being the main
79 differential diagnosis. Hence the interest of a meticulous analysis of the tumor's relationship in MRI.
80 Histological confirmation by biopsy is always indicated [3,4,8,9].

81 Treatment consists of complete excision of the tumor with curettage and bone filling. It should be
82 noted that total resection is not always possible, hence the frequency of recurrence, which reaches
83 25% of cases. Malignant tumor transformation is exceptional [1,2,11].
84

85 4. CONCLUSION

86 Imaging and in particular MRI plays multiple and fundamental roles in the management of chondromyxoid
87 fibroma. MRI provides diagnostic guidance, particularly in the case of atypical localization, a precise study of
88 tumor relationships to guide surgical treatment, and the search for postoperative recurrence.
89
90
91
92
93
94
95
96
97

98
99 **ACKNOWLEDGEMENTS**

100 All authors provided assistance in preparation, design, collection, analysis and interpretation the writing of the manuscript.
101 No funding to declare.
102

103
104 **COMPETING INTERESTS**

105 Authors declare that no competing interests exist
106
107

108
109 **AUTHORS' CONTRIBUTIONS**

110 Hicham Ziani, Ayoub Ettaj, Yassine Regragui and Nabil Elachhab wrote the first draft of the manuscript.
111 Aziza Bentalha, Alae koraichi, Selma Elkettani managed the analyses of the study. All authors read and approved the final
112 manuscript
113
114

115
116 **CONSENT**

117
118 All authors declare that written informed consent was obtained from the patient (for publication of this case report and
119 accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial
120 Board members of this journal.
121
122

123 **ETHICAL APPROVAL**

124
125 All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee
126 and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki
127
128

129
130 **REFERENCES**

- 131
132 [1] Harzallah L, Bouajina E, Rammeh N, Belhadj SK, Ghannouchi M, Kraiem C. Iliac chondroma: a propos
133 d'un
134 Iliac chondroma: a case report. *Tunis Med.* 2005;83(9):578-580
135
136
137 [2] Johnson GC, Christensen M. Benign Chondromyxoid Fibroma of the Iliac Crest. *J Orthop Sports Phys*
138 *Ther.*
139 2018;48(2):122
140
141 [3] Jerbi Omezzine S, Hafsa C, Ben Ghozlan H, Sassi N, Hamza HA, Gannouni A. A rare localization of
142 chondromyxoid
143 Rare location of a chondromyxoid fibroma: the os calcis. *J Radiol.* 2008;89(7-8 Pt 1):897-899
144
145 [4] Yalniz E, Alicioglu B, Yalcin O, Yilmaz B. Non specific magnetic resonance features of chondromyxoid
146 fibroma of the iliac bone. *J BUON.* 2007;12(3):407-40
147
148 [5] Foster DA, Yellen P, Xu L, Saqcena M. Regulation of g1 cell cycle progression distinguishing the
149 restriction point from a nutrient-sensing cell growth checkpoint (s). *Genes Cance* 2010;1(11):1124–31.
150

- 151 [6] Melo AN, Eischen CM. Protecting the genome from mdm2 and mdmx. *Genes Cancer* 2012;3(3- 4):283–90.
152
- 153 [7] Dujardin F, Binh MBN, Bouvier C, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the
154 differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. *Mod*
155 *Pathol*, 2011;24(5):624–37.
156
- 157 [8] Yoshida A, Ushiku T, Motoi T, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade
158 osteosarcoma: correlation with a dedifferentiated subtype. *Am J Surg Pathol* 2012;36(3):423–31.
159
- 160 [9] Martin JW, Chilton-MacNeill S, Koti M, et al. Digital expression profiling identifies RUNX2, CDC5L,
161 MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in
162 paediatric osteosarcoma. *PLoS ONE*.2014;9(5):e95843.
163
- 164 [10] Jeon D, Koh JS, Cho WH, et al. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and
165 MDM2 immunohistochemistry as a diagnostic adjunct. *J Orthopaedic Sci* 2015;20(3):529–37.
166
- 167 [11] Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. *Mod Pathol*
168 2005;18(1):68–74.
169

170

171

172

173

174

175 **FIGURES**

176

177

178




Figure 1: Pelvic MRI in axial T1-weighted sequence without (a) and after (b) gadolinium injection, and in sagittal section T2-weighted sequence before (c) and 5 months after surgical resection (d). The images show a tumor process centered on the right iliac wing, multi-localized, in hyposignal T1 (a), enhanced by Gadolinium (b). The tumor shows a heterogeneous T2 hypersignal, with multiple thick septa in T2 hyposignal (c). There is a compact periosteal reaction opposite, without invasion of adjacent organs.

179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215

216
217
218
219
220
221
222
223
224

225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279

280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309